Evidence map›Paper›PMID 34249232›Full record

ReviewWorld journal of stem cells2021

Potential therapeutic applications of mesenchymal stem cells for the treatment of eye diseases.

Giuliana Mannino, Cristina Russo, Anna Longo, Carmelina Daniela Anfuso, Gabriella Lupo, Debora Lo Furno, Rosario Giuffrida, Giovanni Giurdanella

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of stem cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Giuliana ManninoDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania 95123, Italy.
Cristina RussoDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania 95123, Italy.
Anna LongoDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania 95123, Italy.
Carmelina Daniela AnfusoDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania 95123, Italy.
Gabriella LupoDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania 95123, Italy.
Debora Lo FurnoDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania 95123, Italy. lofurno@unict.it.
Rosario GiuffridaDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania 95123, Italy.
Giovanni GiurdanellaDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania 95123, Italy.
University of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell-based treatments have been extensively explored in the last few decades to develop therapeutic strategies aimed at providing effective alternatives for those human pathologies in which surgical or pharmacological therapies produce limited effects. Among stem cells of different sources, mesenchymal stem cells (MSCs) offer several advantages, such as the absence of ethical concerns, easy harvesting, low immunogenicity and reduced tumorigenesis risks. Other than a multipotent differentiation ability, MSCs can release extracellular vesicles conveying proteins, mRNA and microRNA. Thanks to these properties, new therapeutic approaches have been designed for the treatment of various pathologies, including ocular diseases. In this review, the use of different MSCs and different administration strategies are described for the treatment of diabetic retinopathy, glaucoma, and retinitis pigmentosa. In a large number of investigations, positive results have been obtained by

Indexed as

Diabetic retinopathyEye diseasesGlaucomaMesenchymal stem cellsRegenerative medicineRetinitis pigmentosa

Identifiers

PMID34249232
PMCPMC8246249
OpenAlexW3174930718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.